StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.96−0.22 (-3.06%)

Close on Nov 13, 2026Market cap $459.71MP/E –Yield –

Evolus gross margin

Gross margin is gross profit as a percentage of revenue.

Evolus's gross margin for the twelve months ending Sep 30, 2026 was 66.4%. For fiscal 2025 it was 66.3%, against 68.5% the year before. The highest annual figure on record is 77.1% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202566.3%−2.1
FY2024Dec 31, 202468.5%+0.4
FY2023Dec 31, 202368.1%+7.7
FY2022Dec 31, 202260.4%+4.1
FY2021Dec 31, 202156.3%−11.3
FY2020Dec 31, 202067.6%−9.4
FY2019Dec 31, 201977.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202665.0%−1.4
Q2 FY2026Jun 30, 202668.0%+2.7
Q1 FY2026Mar 31, 202666.9%−1.2
Q4 FY2025Dec 31, 202565.7%−1.0
Q3 FY2025Sep 30, 202566.5%−2.5
Q2 FY2025Jun 30, 202565.3%−5.0
Q1 FY2025Mar 31, 202568.1%−0.2
Q4 FY2024Dec 31, 202466.7%+3.1
Q3 FY2024Sep 30, 202468.9%−0.2
Q2 FY2024Jun 30, 202470.3%+0.2
Q1 FY2024Mar 31, 202468.3%−2.6
Q4 FY2023Dec 31, 202363.6%+1.0
Q3 FY2023Sep 30, 202369.1%+8.9
Q2 FY2023Jun 30, 202370.2%+12.8
Q1 FY2023Mar 31, 202370.9%+9.8
Q4 FY2022Dec 31, 202262.6%+8.3
Q3 FY2022Sep 30, 202260.2%+3.3
Q2 FY2022Jun 30, 202257.4%+0.7
Q1 FY2022Mar 31, 202261.0%+1.1
Q4 FY2021Dec 31, 202154.3%−10.3
Q3 FY2021Sep 30, 202156.9%−15.6
Q2 FY2021Jun 30, 202156.7%−18.4
Q1 FY2021Mar 31, 202159.9%+0.1
Q4 FY2020Dec 31, 202064.6%−16.7
Q3 FY2020Sep 30, 202072.5%+0.8
Q2 FY2020Jun 30, 202075.0%+3.6
Q1 FY2020Mar 31, 202059.8%–
Q4 FY2019Dec 31, 201981.3%–
Q3 FY2019Sep 30, 201971.8%–
Q2 FY2019Jun 30, 201971.4%–

More Evolus figures

See a number that looks wrong?